Table 1.
Characteristics of included literature.
| Source | Criteria | Study population | Age (years) | N (EG/CG) |
Intervention | Outcomes | Follow-up | Side effects | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Western | TCM | EG | CG | EG | CG | ||||||
| Shi ZM 2005 |
RomeII | N.M | Single center | 20-55 | 22-58 | 30/30 | Modified Sini Decoction and TXYF + Acupuncture | OT+DT+BT+MP | A | N.M | N.M |
| Hu FL 2005 |
RomeII | N.M | Single center | 22-68, mean:37 | 20-60, mean:35 | 37/32 | Modified TXYF+ Acupuncture | CGEC+MP+OT | A | N.M | N.M |
| Zhang SY 2006 | RomeII | LQSASDS | Single center | N.M | N.M | 40/25 | Oral: Modified Chaishao Yigong and Xiangsha Pingwei Decoction, Enema: Self-ordained TCM Decoction + Acupuncture | LHS+MP | A | N.M | N.M |
| Yu YG 2007 |
RomeI | N.M | Single center | 44 | 43 | 32/28 | Chang Ling capsule + acupuncture | TDC | A | N.M | N.M |
| Lan YP 2010 |
RomeII | LQSASDS | Single center | 18-62 | 19-61 | 40/40 | Modified TXYF+ Acupuncture | MP+OT | A+O | 6 months | N.M |
| Cao S 2011 |
RomeII | N.M | Single center | N.M | N.M | 70/70 | HXZQ Pill, or HXZQ Capsule, or HXZQ oral liquid + Acupuncture |
RP+MBND | A | N.M | N.M |
| Tang JL 2011 |
Rome III | N.M | Two centers |
N.M | N.M | N.M | Jianpi Huazhuo Tongluo Decoction + Acupuncture | LBP | C+D+F+H+K+M+N+S | N.M | N.M |
| Jiang QY 2013 |
Rome III | LSAASS | Single center | 39.56±11.32 | 37.48±13.79 | 52/54 | Chaihu Shugan Decoction + Acupuncture | OBT | A | N.M | T: 2 cases, C: 1 case |
| Jin J 2013 |
Rome III | N.M | Single center | 42.52±3.73 | 42.94±3.81 | 52/52 | Modified TXYF+ Acupuncture | RP, MBND | A+ T | N.M | T: 2 cases, C: 3 cases |
| Zhou P 2014 |
Rome III | LQSASDS | Single center | 16~64, mean:39.3 |
17~65, mean:38.9 |
45/45 | Modified XYS+ Acupuncture | MP+CGEC+CAECT | A+D+F+L+N+U | 12 weeks | N.M |
| Yan YZ 2014 |
Rome III | LQSASDS | Single center | 38.25 | 36.75 | 52/50 | Modified TXYF+ Acupuncture | PBT+CBLEABCT | A | N.M | C: 3 cases |
| Xu SC 2015 |
Rome III | LQSASDS | Single center | 42.3 | 40.9 | 30/30 | Modified TXYF+ Acupuncture | PBT | A | N.M | N.M |
| Li YX 2015 |
N.M | N.M | Single center | 41.1±7.87 | 40.2±8.56 | 50/48 | Modified XYS + Acupuncture | MP+CGEC | A+C+F+L+N | 12 weeks | no |
| Sun W 2015 |
Rome III | MBND | Single center | 31.5±7.4 | 32.8±8.1 | 60/60 | Jianpi Huazhuo Tongluo Decoction + Acupuncture | PBT | A | N.M | N.M |
| Zhi YC 2016 |
Rome III | LQSASDS | Single center | 42.4±7.4 | 41.8±7.3 | 30/30 | Dunhuang Baoyuan Decoction + Acupuncture | PBT | A | N.M | C: 1case |
| Wang XH 2016 | Rome III | CCSS | Single center | 38.93±5.98 | 39.40±7.94 | 30/30 | BXXX Decoction + Acupuncture | PBT | A+B | N.M | N.M |
| Chen S 2016 |
Rome III | N.M | Single center | 38.21±10.65 | 40.07±9.38 | 60/59 | Shugan Jianpi Zhixie Decoction + Acupuncture | PBT | A+B | N.M | N.M |
| Yang JY 2017 |
Rome III | N.M | Single center | 48.20±4.59 | 47.49±5.23 | 35/35 | Modified SLBZS+ Acupuncture | TMT | A+P+Q+R | 4 weeks | C: 5cases |
| Hou GH 2017 |
Rome III | LSAASS or WOSASS | Single center | 36.75 | 37.55 | 52/52 | CGECC+ Acupuncture | SB+PBT | A+C+D/E+F | N.M | C: 2 cases |
| Wang W 2017 |
Rome III | DBLASS | Single center | 35.2±4.3 | 36.2±5.0 | 102/105 | Self-ordained TCM Decoction + Acupuncture | PBT | A+B+C+D+G+L+M | N.M | C: 3 cases |
| Sun M 2017 |
Rome III | MBND | Single center | 38.79±5.89 | 38.65±5.76 | 30/30 | BXXX Decoction + Acupuncture | PBT | A+B | N.M | N.M |
Annotation:
EG: experiment group; CG: control group; N.M: not mentioned; MBND: mentioned but not described;
CCS: cold-heat complicated syndrome; DBLASS: disharmony between liver and spleen syndrome; LQSASDS: Liver qi stagnation and spleen deficiency syndrome; LSAASS: Liver-qi stagnation and attacking spleen syndrome; WOSASS: weakness of spleen and stomach syndrome;
A: clinical therapeutic efficacy; B: TCM symptom therapeutic effect; C: abdominal pain score; D: abdominal distention score; E: abdominal discomfort score; F: diarrhea score; G: frequency of defecation score; H: mucous stool score; I: borborygmus score; J: property of stool score; K: tenesmus; L: diet condition score; M: sleeping quality score; N: physical strength; O: recurrence rate; P: IBS-QOL score; Q: IBS-BSS score; R: SCL 90; S: SF-36 scale; T: the level of serum inflammatory factor; U: the score of Hamilton Depression Rating Scale
BT: belladonna tablets; BXXX: Banxia Xiexin; CBLEABCT: combined bifidobacterium lactobacillus enterococcus and bacillus cereus tablets (Live); CGECC: compound glutamine enteric-coated capsules; DT: diazepam tablets; HXZQ: Huoxiang Zhengqi; LBP: live bifidobacterium preparation; LHS: loperamide hydrochloride capsules; MP: montmorillonite powder; OBT: otilonium bromide tablets; OT: oryzanol tablets; PBT: pinaverium bromide tablets; SB: saccharomyces boulardii sachets; SLBZS: Shenling Baizhu San; TMT: trimebutine maleate tablets; TXYF: Tongxie Yaofang; XYS: Xiayao San.